Diabetes

Consistent adherence to sodium-glucose cotransporter 2 (SGLT2) inhibitors in individuals with type 2 diabetes reduces the risk of hospitalization, supporting targeted interventions to improve medication-taking behavior.

High-dose vitamin D₃ supplementation reduced diabetes risk by 19% in adults with prediabetes who carry specific vitamin D receptor gene variants.

This study found high out-of-pocket costs for branded diabetes medications in employer-sponsored health plans.

Teplizumab-mzwv is the first disease-modifying therapy available for children as young as 1 year diagnosed with presymptomatic type 1 diabetes.

Receipt of an insurer-provided grocery benefit was associated with decreased rates of diabetes with complications and increased medication adherence among a population with diabetes.

The 2026 Regional Diabetes Summit is taking place from April 28 to 29, 2026, in Wilmington, Delaware.

The FDA has approved the first generic versions of dapagliflozin, expanding access to a widely used SGLT2 inhibitor.

The cap cut quarterly spending by the hundreds and lowered A1c levels but failed to expand the pool of insulin users.

Insulin icodec-abae (Awiqli; Novo Nordisk) is now approved for use in the US, Canada, European Union, Switzerland, and 12 other countries.

Findings show sustained reductions in HbA1c, weight, blood pressure, inflammation, and lipids in patients with T2D and ASCVD or CKD.

Insulin affordability improved for Medicare Part D beneficiaries between 2019 and 2023, with more paying $35 or less for a 30-day supply.

Predictive risk scores created using administrative claims and publicly available social determinants of health data strongly predicted severe diabetes complications for Maryland Medicare fee-for-service beneficiaries.

Study supports broader use of transient elastography to detect advanced liver fibrosis in patients with metabolic dysfunction–associated steatotic liver disease.

National data reveal increasing rates of type 1 and type 2 diabetes among children insured through Medicaid and CHIP.

Orforglipron achieved greater A1C reduction and weight loss than oral semaglutide, highlighting its potential as a needle-free option for type 2 diabetes.

The ready-to-use formulation supports clinicians and families by addressing historical administration challenges.

As utilization of GLP-1s grows for diabetes and weight management, out-of-pocket expenses and affordability concerns may affect broader health care policy discussions.

SGLT2 inhibitors were associated with significantly lower risks of kidney failure, cardiovascular events, mortality, and hepatic decompensation.

Providing monthly produce prescriptions to patients with diabetes at risk for food insecurity did not significantly improve cardiometabolic parameters.

Longer diabetes duration was associated with a significantly increased risk of pancreatic cystic neoplasms.

Across 39 patients in 2 cohorts, rapid microbe reduction, high wound closure, restored warmth and sensation, and avoided amputations were observed.

The FTC first sued Express Scripts, CVS Caremark, and Optum in 2024, claiming anticompetitive and unfair rebating practices surrounding insulin.

A randomized clinical trial found a voice-enabled virtual assistant reduced mental distress and improved quality of life, self-care, and glycemic control.

Few adults with diabetes in Mexico achieve combined CVD risk factor control, highlighting gaps in blood pressure, cholesterol, and glycemic management.

Initiating SGLT2is was linked to lower risks of chronic kidney disease and fewer acute kidney injury events than GLP-1 RAs in metformin-treated type 2 diabetes.